logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Agenus Inc.


USPTO Granted Patents = 52



Trademarks = 2

Forward Citations = 121

Loading Chart...
Loading Chart...

63 inventors (with patents filed for the assignee):

goldMedal Marc A Van Dijk (36 out of 42 patents)

silverMedal Nicholas Stuart Wilson (34 out of 35 patents)

bronzeMedal Taha Merghoub (26 out of 42 patents)

4.  David Schaer (26 out of 26 patents)

5.  Gerd J Ritter (26 out of 58 patents)

6.  David Adam Savitsky (22 out of 22 patents)

7.  Cornelia Anne Mundt (17 out of 19 patents)

8.  Dennis John Underwood (17 out of 29 patents)

9.  Jedd David Wolchok (14 out of 35 patents)

10.  Volker Seibert (12 out of 14 patents)

11.  Ekaterina Vladimirovna Breous-Nystrom (12 out of 14 patents)

12.  Jeremy Dale Waight (11 out of 11 patents)

13.  Olivier Léger (9 out of 9 patents)

14.  Takemasa Tsuji (9 out of 14 patents)

15.  Daniel Hirschhorn-Cymerman (8 out of 8 patents)


Core Competencies:
Anti-ILT4 Antibodies
Anti-CTLA-4 Antibodies
Anti-LAG-3 Antibodies
Anti-TIM-3 Antibodies
Anti-GITR Antibodies
Anti-PD-1 Antibodies
Anti-OX40 Antibodies
Anti-TIGIT Antibodies
Nucleic Acids Encoding Antibodies
MHC Class I Phospho-Peptide Antigens
Cancer Vaccines
Antigen-Binding Fragments

52 patents:

1. 12344670 - Anti-ILT4 antibodies and antigen-binding fragments (2025-07-01),
2. 12246066 - Anti-CTLA-4 antibodies and methods of use thereof (2025-03-11),
3. 12187795 - Anti-LAG-3 antibodies and methods of use thereof (2025-01-07),
4. 12011481 - Anti-TIM-3 antibodies and methods of use thereof (2024-06-18),
5. 11993653 - Antibodies and methods of use thereof (2024-05-28),
6. 11993651 - Anti-lag-3 antibodies and methods of use thereof (2024-05-28),
7. 11897962 - Anti-GITR antibodies and methods of use thereof (2024-02-13),
8. 11897957 - Anti-ILT4 antibodies and antigen-binding fragments (2024-02-13),
9. 11897956 - Anti-ILT4 antibodies and antigen-binding fragments (2024-02-13),
10. 11839653 - Anti-TIM-3 antibodies and methods of use thereof (2023-12-12),
11. 11718669 - Anti-TIGIT and anti-CD96 antibodies (2023-08-08),
12. 11692042 - Anti-CD73 antibodies and methods of use thereof (2023-07-04),
13. 11680098 - Antibodies that specifically bind human CD96 (2023-06-20),
14. 11638755 - Anti-CTLA-4 antibodies and methods of use thereof (2023-05-02),
15. 11472883 - Methods of administering anti-OX40 antibodies (2022-10-18),
Agenus is an immuno-oncology company focused on the discovery and development of innovative therapies to treat cancer patients. The company's approach involves harnessing the power of the immune system to fight against cancer. Agenus has a diverse pipeline of antibodies, vaccines, and adoptive cell therapies targeting various types of cancer. With a mission to extend and improve the lives of cancer patients, Agenus's research and development efforts strive to deliver breakthrough treatments that can make a meaningful difference in oncology.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
52 Patents

#19 in Lexington, MA

#374 in Massachusetts

#6,544 in US

#13,161 in the World

...
Lexington, MA, United States of America

Agenus Inc.

Forward Citations = 121

63 inventors:

goldMedal Marc A Van Dijk (36 out of 42 patents)

silverMedal Nicholas Stuart Wilson (34 out of 35 patents)

bronzeMedal Taha Merghoub (26 out of 42 patents)

4.  David Schaer (26 out of 26 patents)

5.  Gerd J Ritter (26 out of 58 patents)

Please report any incorrect information to support@idiyas.com
Loading…